Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp165 | Cell biology: osteoclasts and bone resorption | ECTS2014

Foreign body giant cells do not have the capacity to resorb bone

ten Harkel Bas , Schoenmaker Ton , de Vries Teun J. , Everts Vincent

Background: Osteoclasts are unique multinucleated cells that originate from the fusion of monocytes. They are the only cells known to be capable of bone resorption. Interestingly, the foreign body multinucleated giant cell (FBGC) arises from the same lineage as the osteoclast, and they share numerous similar characteristics, among which the expression of tartrate resistant acid phosphatase (TRAcP). Yet, it is not known whether the FBGC has the capacity to resorb bone.<p cl...

ba0003pp225 | Osteoporosis: evaluation and imaging | ECTS2014

Utilizing bisphosphonate binding kinetics and soft tissue-derived input functions to differentiate changes in long bone and vertebra bone metabolism using in vivo fluorescent molecular tomography

Tower Robert J , Muller Marc , Will Olga , Tiwari Sanjay , Gluer Claus C , Campbell Graeme M

Bone resorption and formation occur in a tightly regulated fashion reflecting the coupled activities of osteoclasts and osteoblasts. Several pathological conditions perturb this balance, including osteoporosis and skeletal metastases. In the case of metastases, the uncoupling of resorption and formation activities contributes to disseminated tumor cells homing to the bone and to tumor growth within the bone in highly localized regions. Therefore, a site-specific marker of bone...

ba0003pp297 | Osteoporosis: treatment | ECTS2014

Contribution of circulating sclerostin and estradiol for inadequate response to bisphosphonate therapy in women with postmenopausal osteoporosis

Munoz-Torres M , Diez-Perez A , Olmos J M , Nogues X , Sosa M , Diaz-Curiel M , Perez-Castrillon J L , Perez-Cano R , Torrijos A , Jodar E , Rio L Del , Caeiro-Rey J R , Rubio V Avila , Garcia-Martin A , Reyes-Garcia R , Garcia-Fontana B , Gonzalez-Macias J , Morales-Santana S

Bisphosphonate treatment reduces fracture risk in women with postmenopausal osteoporosis. However, some patients have an inadequate response to treatment. Estradiol and sclerostin play an important role in bone metabolism. Sclerostin is an endogenous inhibitor of osteoblastic activity and estrogen deficiency increases osteoclast activity and bone resorption.We examined the influence of both measures on fracture incidence in postmenopausal osteoporosis in...

ba0003pp322 | Osteoporosis: treatment | ECTS2014

Non attendance at a Bone Health Clinic following hip fracture

Maher Niamh , Steen Georgina , Fallon Nessa , Lannon Rosaleen , Casey Miriam , Walsh J B

Hip fractures are a major cause of burden in terms of mortality, disability, and costs. In Ireland, 3000 hip fracture occur annually and is expected to increase over the coming years1. Estimated cost of hip fractures is &z.euro;14 300/admission2. Outpatient non-attendance is a source of inefficiency, wasting time, resources and lengthens waiting lists. Non attendees have a significant negative impact on productivity, their own care and resources. In 2008,...

ba0004p32 | (1) | ICCBH2015

Characteristics of Malawian children undergoing corrective bone surgeries of rickets-like lower limb deformities

Braithwaite Vickie S , Greenwood Carla L , Bishop Nicholas J , Cashman John , Prentice Ann

Cases of non-vitamin D deficiency rickets have been reported in African countries including The Gambia, South Africa and Nigeria where the likely aetiology is a chronically low dietary calcium intake. Additional aetiological factors in Gambian studies are iron deficiency leading to a disruption in phosphate metabolism.Surgical correction of pathological rickets-like lower-limb deformities is the most common operation performed at the Beit Cure Orthopaedi...

ba0004p127 | (1) | ICCBH2015

The outcomes of a standardized approach to managing metabolic bone disease of prematurity

Chin Lit Kim , Doan John , Teoh Yvonne Sui Lien , Stewart Alice , Forrest Peter , Simm Peter J

Metabolic bone disease (MBD) of prematurity is a well-recognized complication of preterm birth. Yet there is limited evidence for the optimal assessment, monitoring, and subsequent bone health management.Retrospective audit of 171 infants born <32 weeks’ gestation between November 2012 and January 2014 at three Monash Health neonatal units (Melbourne, Australia) was undertaken. Infants had mean gestational age (GA) 28.6±2.1 weeks and birth ...

ba0004p166 | (1) | ICCBH2015

The role of AMPK pathway in mediating the effects of metformin on mesenchymal stem cell differentiation

Chen Suet Ching , Brooks Rebecca , Ahmed Syed Faisal , Yarwood Stephen J

Introduction: Insulin sensitising agents are reported to have a diverse range of effects on bone with metformin exerting positive effects and thiazolidinenediones (TZDs) exerting negative effects. 5’AMP-activated protein kinase (AMPK) plays a critical role in cellular energy homeostasis. It is widely expressed in the body and can be activated by metformin.Objective:: We investigated the role of AMPK pathway in mediating the effects of metformin on t...

ba0005cabs.oc2.4 | Oral Communications | ECTS2016

Peripheral tumour re-growth following combination therapy – role of the bone microenvironment

Haider Marie-Therese , Ottewell Penelope D. , Brown Nicola J. , Lefley Diane V. , Holen Ingunn

Background: Cancer patients often receive a combination of drugs that target both the microenvironment and the tumour cells. However, the role of the bone microenvironment (BME) in mediating peripheral breast cancer growth remains poorly understood. This is the first study to determine whether reduced subcutaneous tumour growth following combination therapy is due to direct interactions between the drugs and tumour cells or through zoledronic acid induced alterations to the BM...

ba0005oc5.3 | Risk factors for fracture, Pagets disease of bone and musle and bone | ECTS2016

Osteoprotegerin autoantibodies are independently associated with low hip bone mineral density and increased fracture risk in patients with ankylosing spondylitis

Hauser Barbara , Zhao Sizheng , Visconti Micaela R , Riches Philip L , Goodson Nicola J , Ralston Stuart H

Osteoporosis and vertebral fractures are recognised complications of ankylosing spondylitis (AS) but the underlying causes are incompletely understood. Osteoprotegerin (OPG) is a decoy receptor for RANK-L and inhibits osteoclastogenesis. We have previously demonstrated that antibodies to OPG (OPG-Ab) are associated with osteoporosis and increased bone turnover in patients with autoimmune diseases. The aim of this study was to determine whether OPG-Abs were detectable in AS pat...